NICE says drug to treat Batten disease cannot be recommended for NHS use because company is unable to address concerns about long-term effectiveness

NICE has published draft guidance which confirms its earlier decision not to recommend cerliponase alfa (also called Brineura and made by Biomarin) for children with Batten disease – a very rare inherited condition affecting between 1 and 6 babies each year in the UK.

Read article

Shared Learning Awards: Judges reveal 20 shortlisted entries to be displayed at NICE annual conference

More than 60 entries received from organisations across the country which highlight how they put NICE guidance into practice

Read article

NICE draft guidance recommends pertuzumab for new breast cancer indication after improved price offer from company

NICE has published final draft guidance recommending pertuzumab (Perjeta, Roche) for treating early HER2-positive breast cancer in people whose disease has spread to their lymph nodes.

Read article

NICE provides first scientific advice on patient preference study design

The NICE Scientific Advice team, working with the Science Policy and Research team at NICE, has provided its first piece of advice on the design of a patient preference study.

Read article

Latest news headlines